Conditions: Migraine Headache
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 414
Healthy volunteers: no

Brief summary:
The main purpose of this study is to evaluate whether the study drug known as galcanezumab is safe and effective in the prevention of migraine headaches.

Detailed description:

Arms:
arm 1: 5mg of galcanezumab given as subcutaneous (SQ) injections once every 28 days during a 12 week treatment period. arm 2: 50mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period. arm 3: 120mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period. arm 4: 300mg of galcanezumab given as SQ injections once every 28 days during a 12 week treatment period. arm 5: Placebo given as SQ injections once every 28 days during a 12 week treatment period.

Interventions: intervention 1: Galcanezumab intervention 2: Placebo
Intervention descriptions: intervention 1: Administered SQ intervention 2: Administered SQ

Protocol document: